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Background:Managementof acute coronarysyndrome (ACS) patientswith nonobstructiveepicardial coronary
artery disease (CAD) remains poorly understood.
Hypothesis: Acute coronary syndrome patients with nonobstructive CAD are less likely to receive effective
cardiac medications upon discharge from the hospital.
Methods: We identified patients hospitalized with ACS that underwent coronary angiography and had
a 6-month follow-up. Patients were grouped by CAD severity: nonobstructive CAD (<50% blockage in all
vessels) or obstructiveCAD (50%blockage in1 vessels). Datawere collectedondemographics,medications
at discharge, and adverse outcomes at 6 months, for all patients.
Results: Of the 2264 ACS patients included in the study: 123 patients had nonobstructive CAD and 2141 had
obstructive CAD. Cardiac risk factors including hypertension and diabetes were common among patientswith
nonobstructiveCAD. Men andwomen with nonobstructiveCAD were less likely to receive cardiac medications
compared to patientswith obstructive CAD including aspirin (87.8% vs 95.0%, P = 0.001), β-blockers (74.0%
vs 89.2%, P < 0.001), or statins (69.1% vs 81.2%, P = 0.001). No gender-related differences in discharge
medications were observed for patients with nonobstructive CAD. However, women with nonobstructive
CAD had similar rates of cardiac-related rehospitalization as men with obstructive CAD (23.3% and 25.9%,
respectively).
Conclusions:Patientswith nonobstructiveCADare less likely to receiveevidence-basedmedications compared
to patients with obstructive CAD, despite the presence of CAD risk factors and occurrence of an ACS event.
Further research is warranted to determine if receipt of effective cardiac medications among patients with
nonobstructiveCAD would reduce cardiac-related events.
Introduction
Approximately 10% to 25% of women and 6% to 10% of
men with acute coronary syndrome (ACS) have ‘‘normal’’
or nonobstructive atherosclerotic coronary artery disease
(CAD) defined as <50% stenosis.1 Although the risk for
adverse events post-ACS is lower in nonobstructive CAD
patients, this group is not event-free.2 Data from the
Thrombolysis in Myocardial Infarction trials (TIMI 11B,
TIMI 16, TIMI 22) suggest that 10% of such patients may
suffer either myocardial infarction (MI), unstable angina
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(UA) requiring hospitalization, revascularization, stroke, or
death.1
Currently,data on ACS patientswith nonobstructiveCAD
is limited. Prior studies have observed that women admitted
for cardiac-related diagnoses, are more likely to have
nonobstructive CAD on coronary angiogram,3 – 6 however
the management of nonobstructive CAD is not well studied.
Understanding the risk factor profile, ACS type, and the
receipt of use of cardiac medications among women and men
with nonobstructive CAD may add insight to current prac-
tice patterns and clinical outcomes. Therefore,we evaluated
the clinical factors and rate of receipt at discharge for
aspirin, β-blockers, angiotensin-converting enzyme (ACE)
inhibitors, statins, and clopidogrel or ticlopidine, among
men and women ACS patients with nonobstructive epicardial
CAD compared to men and women ACS patients with
obstructive epicardial CAD.
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Methods
All patients admitted to the University of Michigan Health
System’s ACS registry (n = 3514) between January 1999
and August 2004 with a diagnosis of ACS were eligible
for study inclusion. Patients who did not receive coronary
angiographyduring the index hospitalizationor did not have
6-month follow-up data were excluded (n = 1250). Acute
coronary syndrome was defined as UA, ST-segment ele-
vation myocardial infarction (STEMI), or non-ST-segment
elevation myocardial infarction (NSTEMI). The diagnosis
of ACS was documented by standardized definitions which
included the presence of symptoms consistent with acute
coronary insufficiency, increases in cardiac enzymes (CK-
MB >2 times upper limit of the hospital’s normal range
and/or positive troponin I), and/or positive acute electro-
cardiographic changes including: (1) transient ST-segment
elevations of 1 mm in 2 or more contiguous leads, (2) ST-
segment depressions of 1 mm, (3) new T-wave inversions
of 1 mm, and (4) new left bundle branch block.7,8 Patients
under the age of 18 were excluded from the study. Full
details of the University of Michigan Health System’s ACS
registry have been published previously.9
Independent variables included demographics (age, sex,
race) and medical history as documented in the patients’
medical records (smoking status, history of angina, MI,
hyperlipidemia, peripheral vascular disease, diabetes mel-
litus, hypertension, prior stroke), and CAD family history
(defined as having any blood relative [parents, siblings,
children] with a history of angina, MI, and/or sudden
cardiac death before the age of 55). Information regard-
ing ACS type and in-hospital events was collected via chart
reviewas describedabove. Dischargemedicationsthat were
assessed included the following: aspirin, β-blockers, ACE
inhibitors, statins, and clopidogrel or ticlopidine. Patients
with contraindications to these medications were excluded
from the study. Measured outcomes of patients included in-
hospital recurrent ischemia (defined as further symptoms
of angina with or without ischemic electrocardiographic
changes while in the hospital), and 6-month outcomes
such as rehospitalization for cardiac reasons (defined as
any unscheduled rehospitalization/s for heart disease),
nonfatal MI, nonfatal stroke, all-cause death, and major
adverse cardiovascular events (MACE; defined as death
from cardiac causes, nonfatal MI, nonfatal stroke, rehospi-
talization for cardiac causes, and/or unscheduled coronary
revascularization).
Study site coordinators, physicians, and cardiology
research nurses were trained and given a manual of
operations to correctly identify patients eligible for study
inclusion and accurately abstract the data from medical
charts. Data not within the set limit ranges, inconsistencies,
and/or unrecorded fields were flagged and then returned
for clarification and correction. The 6-month follow-up data
were obtained via telephone calls. At least 3 phone call
attemptswere made to contact patients to query their health
status before any medical record data collection occurred.
All aspects of this study were approved by the institutional
review board at the University of Michigan and informed
consent was obtained from all patients.
Acute coronary syndrome patients who underwent
cardiac catheterization were divided into 2 groups:
(1) nonobstructive CAD (<50% stenosis in all vessels) and
(2) obstructive CAD (50% stenosis in 1 vessels), based
on the angiographers’ interpretations. A cutoff of 50% was
used based on previous studies.5,10 Within each CAD stra-
tum, differences in characteristics were determined by sex.
Differences in characteristics between those with and with-
out nonobstructive CAD were also compared. A P value
of 0.05 was considered statistically significant. For test-
ing differences between 2 groups, either the t test or the
Wilcoxon rank sum test for continuous variables was used
as indicated by the data. For categorical data, the χ2 statistic
was used with a Yates’ correction factor as indicated by the
data. A Fisher exact test was used if the expected number
of observations in any cell was <5.
Bivariate analyses among patients in both groups of CAD
severity were performed to determine if a relationship
existed between prescribing at least 3 of 4 cardiac
medications (aspirin, β-blocker, ACE inhibitor, statin) at
the time of discharge and rehospitalization rates for cardiac
causes. We opted to evaluate 3 out of 4 of these medications
(excluding clopidogrel and ticlopidine) as the evidence to
support the prescription of clopidogrel post-ACS had not
been published until 2001—2 years after the present study
patients were enrolled.11 Statistical analysis software 8.2
(SAS Institute, Cary, NC) was used for all analyses.
Results
A total of 2264 ACS patients were included in the study
and were followed for 6 months post-hospital discharge.
Of these, 67.6% (n = 1530) were men and 93.6% (n = 2119)
were white (Table 1). The majority of patients were classified
as having obstructive CAD (94.6%) of which 1473 were men
and 668 were women. Nonobstructive CAD was observed in
123 patients (5.4%), of which 57 were men and 66 were
women. Women were significantly more likely to have
nonobstructive CAD upon angiography compared to men
(9.0% vs 3.7%, P < 0.001). Nonobstructive CAD patients
averaged 4 years younger, were less likely to be white, and
less likely to have a prior history of angina or hyperlipidemia,
compared to obstructive CAD patients. Rates of traditional
cardiovascular risk factors were similar among the 2
groups including current smoking, family history of CAD,
diabetes, hypertension, peripheral vascular disease, and
stroke. Prevalence of diabetes ranged from 21.2% among
women with nonobstructive CAD to 32.2% for women
with obstructive CAD. High rates of hypertension were
also observed among the women (70.8% for women with
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Clinical Investigations continued
Table 1. Demographic, Medical History, ACS Characteristics, and In-hospital Events of Coronary Artery Disease Patients Stratified by Severity of Coronary
Artery Disease Status (n = 2264)a



















n (%) P1 P2
Age, mean (SD), y 58.7 ± 15.4 54.4 ± 15.0 62.3 ± 14.9 0.004 62.7± 12.8 61.4 ± 12.4 65.4 ± 13.2 <0.001 <0.01
Nonwhite race 12 (16.4) 5 (13.5) 7 (19.4) 0.49 133 (8.7) 79 (7.6) 54 (11.3) 0.02 0.03
Past medical history
Current smoking 27 (22.0) 188 (31.6) 9 (13.6) 0.02 558 (26.3) 397 (27.2) 161 (24.2) 0.15 0.29
Angina 33 (26.8) 14 (24.6) 19 (28.8) 0.60 928 (43.4) 624 (42.4) 304 (45.6) 0.17 <0.001
Myocardial infarction 42 (34.1) 23 (40.4) 19 (28.8) 0.18 786 (36.7) 537 (36.5) 249 (37.3) 0.72 0.57
Hyperlipidemia 59 (48.4) 32 (56.1) 27 (41.5) 0.11 1374 (64.3) 941 (64.0) 433 (64.9) 0.69 <0.001
CAD family history 39 (45.3) 15 (37.5) 24 (52.2) 0.17 528 (49.8) 367 (50.5) 161 (48.3) 0.52 0.43
PVD 8 (6.6) 5 (8.8) 3 (4.6) 0.36 253 (11.9) 160 (10.9) 93 (14.0) 0.04 0.07
Diabetes mellitus 29 (23.6) 15 (26.3) 14 (21.2) 0.51 601 (28.1) 385 (26.2) 216 (32.3) 0.003 0.28
Hypertension 75 (61.5) 29 (50.9) 46 (70.8) 0.02 1461 (68.4) 946 (64.4) 515 (77.2) <0.001 0.11
Prior stroke 9 (7.3) 2 (3.5) 7 (10.6) 0.13 186 (8.7) 106 (7.2) 80 (12.0) <0.001 0.60
ACS type
STEMI 18 (14.6) 10 (17.5) 8 (12.1) 0.40 539 (25.2) 392 (26.6) 147 (22.0) 0.023 0.008
NSTEMI 81 (65.9) 32 (56.1) 49 (74.2) 0.04 1192 (55.7) 808 (54.9) 384 (57.5) 0.26 0.03
UA 24 (19.5) 15 (26.3) 9 (13.6) 0.08 410 (19.1) 273 (18.5) 137 (20.5) 0.28 0.92
Abbreviations: CAD, coronary artery disease; LV, left ventricular; NSTEMI, non-ST-elevation myocardial infarction; PVD, peripheral vascular disease; SD,
standard deviation; STEMI, ST-elevationmyocardial infarction; UA, unstable angina; VF, ventricular fibrillation.
a Data are presented as number (percentage) unless otherwise indicated. Percentages are based on available data.
P1 represents the difference betweenmen andwomenwithin eachCAD category; P2 represents the difference betweenCAD categories among all patients.
nonobstructive CAD and 77.2% for women with obstructive
CAD).
Among ACS patients with nonobstructive CAD, women
were on average older than men (Table 1). Women were
more likely to have a prior history of hypertension, but
less likely to smoke. Other cardiovascular risk factors were
similar between the men and women with nonobstructive
CAD.
Among patients with obstructiveCAD, women were older
than men and were more likely to be nonwhite (11.3% vs
7.6%, P = 0.02; Table 1). Women reported similar rates of
current smoking compared to men, but were more likely
to have a history of peripheral vascular disease, diabetes
mellitus, hypertension, or prior stroke, compared to men
with obstructive CAD. No sex-related differences were
observed for a history of angina, prior MI, hyperlipidemia,
or family history of CAD, among obstructive CAD patients.
In regards to ACS type, patients with obstructive CAD
were more likely to present with a STEMI compared to
those with nonobstructive CAD, while rates of NSTEMI
were higher among those with nonobstructiveCAD. Among
nonobstructive CAD patients, 57 of the 66 women had
positive biomarkers and 42 of the 55 men had positive
biomarkers.Rates of UA were similar between the 2 groups.
Among men and women with nonobstructive CAD, women
were more likely to presentwith NSTEMI comparedto men,
while no statistically significant differences were observed
for men and women with obstructive CAD and NSTEMI.
Rates of STEMI were higher among men with obstructive
CAD compared to women with obstructive CAD.
Receipt of cardiac medications at time of discharge was
similar for men and women with nonobstructive CAD,
but less frequently prescribed, as compared to those
with obstructive CAD (Table 2). Compared to patients
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Table 2. Discharge Medications Administered to Coronary Artery Disease Patients Stratified by Severity of Coronary Artery Disease



















n (%) P1 P2
Aspirin 108 (87.8) 51 (89.5) 57 (86.4) 0.60 2034 (95.0) 1414 (96.0) 620 (92.8) 0.002 0.001
β-Blockers 91 (74.0) 40 (70.2) 51 (77.3) 0.37 1910 (89.2) 1328 (90.2) 582 (87.1) 0.04 <0.001
ACE inhibitors 77 (62.6) 36 (63.2) 41 (62.1) 0.91 1404 (65.6) 992 (67.3) 412 (61.7) 0.01 0.50
Statins 85 (69.1) 39 (68.4) 46 (69.7) 0.88 1739 (81.2) 1217 (82.6) 522 (78.1) 0.01 0.001
Clopidogrel or ticlopidine 44 (35.8) 23 (40.4) 21 (31.8) 0.33 1567 (73.2) 1088 (73.9) 479 (71.7) 0.30 <0.001
3 of 4 medicationsa 44 (69.0) 37 (64.5) 48 (72.7) 0.35 1839 (85.9) 1292 (87.7) 547 (81.9) <0.001 <0.001
Abbreviations: ACE, angiotensin-converting enzyme; CAD, coronary artery disease.
a The 4 medications considered were aspirin, β-blockers, ACE inhibitors, and statins.
P1 represents the difference betweenmen andwomenwithin eachCAD category; P2 represents the difference betweenCAD categories among all patients.
Table 3. Six-month Follow-up Events Among Coronary Artery Disease Patients Stratified by Severity of Coronary Artery Disease Status



















n (%) P1 P2
Rehospitalization 17 (15.6) 4 (7.5) 13 (23.2) 0.02 547 (29.1) 335 (25.9) 212 (36.0) <0.001 0.002
Myocardial infarction 1 (1.0) 1 (2.0) 0 (0.0) 0.31 106 (7.0) 65 (6.3) 41 (8.5) 0.12 0.02
Stroke 0 (0.0) 0 (0.0) 0 (0.0) . . . 20 (1.1) 14 (1.1) 6 (1.0) 0.91 0.27
Revascularization (unscheduled) 1 (1.0) 1 (2.2) 0 (0.0) . . . 145 (8.3) 83 (6.9) 62 (11.4) 0.002 0.009
Death 5 (4.1) 2 (3.5) 3 (4.5) 0.77 80 (3.7) 44 (3.0) 36 (5.4) <0.01 0.85
MACE 21 (17.1) 7 (12.3) 14 (21.2) 0.19 634 (29.6) 388 (26.3) 246 (36.8) <0.001 0.003
Abbreviations: CAD, coronary artery disease; MACE, major adverse cardiovascular events including death from cardiac causes, nonfatal myocardial
infarction, and nonfatal stroke.
P1 represents the difference betweenmen andwomenwithin eachCAD category; P2 represents the difference betweenCAD categories among all patients.
with obstructive CAD, patients with nonobstructive CAD
were less likely to be discharged on aspirin, β-blockers,
statins, and clopidogrel or ticlopidine, with a similar trend
observed for receipt of ACE inhibitors. Overall, patients
with nonobstructive CAD were significantly less likely to
receive 3 of 4 of these evidence-based medications (EBMs).
Of note, women with nonobstructive CAD were less likely
to receive aspirin, β-blockers, ACE inhibitors, and statins
upon discharge as compared to the men.
As expected, 6-month cardiac outcomes were lower
among those with nonobstructive CAD (Table 3). No
statistical difference was noted for 6-month mortality when
comparing ACS patients with nonobstructive CAD and
obstructive CAD, however the event rate was low for
both groups. The rates of rehospitalization among women
with nonobstructive CAD (23.2%) were similar to that
observed for men with obstructive CAD (25.9%), and
significantly higher than that of men with nonobstructive
CAD. In terms of discharge medications and rates of
cardiac-related rehospitalization, no significant differences
were observed among men and women who received
>3 of 4 EBMs (aspirin, β-blockers, ACE inhibitors, and
statins) compared to those who did not. Of the 17 patients
with nonobstructive CAD, who were rehospitalized within
6 months, approximately one-third did not receive 3 of 4
EBMs (64.7% vs 35.3%); however, the number of subjects
rehospitalizedwas extremelysmall which limited our power
to detect meaningful differences.
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Clinical Investigations continued
Discussion
In this large cohort from a single academic center, we
observed approximately 6% of men and women admitted
with ACS had nonobstructive CAD by coronary angiogra-
phy, with a higher proportion among women compared to
men. Both men and women with nonobstructive CAD had
significantrates of cardiovascularrisk factors, and were less
likely to receive cardiac medications including aspirin, β-
blockers, statins, and clopidogrel or ticlopidine, at the time
of discharge compared to patients with obstructive CAD.
Furthermore, women with nonobstructive CAD had sim-
ilar rates of cardiac-related rehospitalization as men with
obstructive CAD within the first 6 months of discharge from
the index hospitalization.
The incidence of ACS patients with nonobstructive
CAD in our study is similar to what has been observed
in previous reports of ACS.1,3,10 The higher rates of
nonobstructive CAD among female patients has been
observed in several other studies as well.10,12 Data from
3 TIMI trials noted rates of nonobstructive CAD between
9% to 25%,1 while the Can Rapid Risk Stratification of
Unstable Angina Patients Suppress Adverse Outcomes
With Early Implementation of the ACC/AHA Guidelines
(CRUSADE) Quality Improvement Initiative observed 8.6%
of the study population had nonobstructive CAD.13 The
Women’s Ischemia Syndrome EvaluationStudy (WISE) and
Global Utilization for Streptokinase and TPA for Occluded
Coronary Arteries (GUSTO) IIb studies also reported
significant rates of nonobstructive CAD among women
referred for angiography.5,6 In our investigation, women
with nonobstructive CAD were more likely to be older and
were more likely to have chronic hypertension compared
to the men, while both men and women had similar rates
of diabetes. However, our observations are consistent with
prior studies which have examined gender differences in
ACS patients, where women were older and have a higher
prevalence of hypertension compared to men.6,14 – 18
We observed a significantly lower rate of receipt for
cardiac medication among patients who were found to
have nonobstructive CAD, despite the high prevalence of
cardiovascular risk factors. In a similar study, 180 ACS
patients with nonobstructive CAD were observed to have
lower rates of receipt for aspirin, ACE-inhibitors,β-blockers,
and clopidogrel.12 In our cohort, almost 40% of patients with
nonobstructive CAD did not receive ACE-inhibitors at the
time of discharge, despite the diagnosis of ACS and high
rates of hypertension and diabetes in this group.
We found no significant differences in all-cause mortality
between men and women with nonobstructive CAD. We
noted 4% of patients with nonobstructive CAD died during
the 6-month follow-up, in contrast to a similar study by
Dwyer et al which observed no deaths or recurrent MI
among ACS patients with nonobstructive CAD.12 However,
rates of readmissions were similar between the 2 studies.
Women with nonobstructive CAD were more than 3
times more likely to be rehospitalized for cardiac causes
than men. Furthermore, women with nonobstructive CAD
had comparable rehospitalization rates to that of men with
obstructive CAD. While the presented data do not provide
definitive reasons for these observations, it is plausible that
rehospitalizationwas due to recurrent episodesof chest pain
from microvascular disease, particularly given the CAD risk
factor burden observed in the group with nonobstructive
CAD. Unfortunately, given the small numbers of patients
with nonobstructive CAD in this cohort, it is not possible to
examine multiple factors via multivariate analysis. Prior
studies suggest a significant benefit to the receipt of
medications in ACS patients in terms of recurrent cardiac
events and progression of coronary atherosclerosis.19 – 21 It
remains to be seen whether risk factor modification among
men and women with nonobstructive CAD would result in
decreased rehospitalization.
Several limitationsof this study exist. This study included
patients with documented ACS who were part of a large
ongoing registry in 1 academic medical center; however,
the numbers of men and women with nonobstructive CAD
is small. This cohort includes a spectrum of ACS patients
and as such offers a ‘‘real-life’’ perspective of ACS treatment
by including a heterogeneousstudy populationas compared
with randomized control trial study populations. However, as
this study has an observational design, inherent limitations
and potential biases (including selection bias) may exist.
For the present analysis, only patients who underwent
coronary angiography were included and therefore this
information may not be generalizable to patients who do
not receive cardiac angiography. Angiographic data were
based on clinical reports and was not adjudicated by a core
lab, and thus may be subject to some degree of between-
person variability. Second, while we do follow patients for
up to 6 months, we do not have information regarding
adherence to medications which can certainly play a factor
in clinical outcomes.Finally, categorizingof CAD severityas
obstructive CAD based on our criteria meant grouping ACS
patients with less severe disease together with patients with
multiple and/or more severely stenotic lesions; however,
the primary aim of this study was to examine management
among ACS patients with nonobstructive CAD. In addition,
this type of categorization of CAD severity has been done in
prior studies.4,10,21
Conclusion
Significant improvements in the management of patients
presenting with ACS have occurred over the past several
decades. However, we observed lower rates of receipt of
cardiac medications at the time of discharge among men
and women ACS patients with nonobstructive disease.
Increased use of cardiac medications and modification
of risk factors among patients with nonobstructive CAD
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may reduce their rehospitalization rates and decrease their
progression of coronary atherosclerosis, though larger,
long-term studies are needed to further examine this
hypothesis.
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